Pharma large Sanofi opens $595 million vaccine facility in Singapore to organize for potential pandemics
A Sanofi emblem sits on the facade of the corporate’s headquarters on December 11, 2020 in Gentilly close to Paris, France.
Chesnot | Getty Photos
SINGAPORE — French pharmaceutical large Sanofi on Wednesday opened a 800 million Singapore greenback ($595 million) “evolutive vaccine facility,” or EVF, in Singapore — the one such facility the corporate has exterior of France.
This plant, referred to as Modulus, can change between making completely different vaccines or remedies in a matter of days, in comparison with a number of weeks or months in additional typical services. It is usually capable of be tailored to fabricate as much as 4 vaccines or biopharmaceuticals concurrently.
The power will contribute about 200 jobs to the city-state, together with bioprocess engineers, automation specialists and knowledge analysts, and might be totally operational by mid-2026.
Sanofi mentioned in a launch that the ability holds the potential to considerably bolster pandemic preparedness.
“By establishing the groundwork for essential manufacturing modules now, Modulus can guarantee a swift and focused response to any future well being wants, together with potential pandemics,” the corporate mentioned.
That is a part of the corporate’s 900 million euro funding to develop two new EVFs globally over 5 years. The opposite EVF is in Neuville-sur-Saône, France.
